RemeGen Co (FRA:REG) Return-on-Tangible-Asset: 78.53% (As of Dec. 2025)


FRA:REG RemeGen Co Ltd FRA:REG
39 GF Score
Price €9.36
GF Value €21.08
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is RemeGen Co Return-on-Tangible-Asset?

RemeGen Co FRA:REG -2.42% 39 Return-on-Tangible-Asset is 78.53% as of Dec. 2025. GuruFocus rates FRA:REG with a GF Score™ of 39/100 and a GF Value™ of €21.08 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,413 Biotechnology companies, RemeGen Co ranks better than 95.26% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. RemeGen Co's annualized Net Income for the quarter that ended in Dec. 2025 was €611.3 Mil. RemeGen Co's average total tangible assets for the quarter that ended in Dec. 2025 was €778.4 Mil. Therefore, RemeGen Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 78.53%.

The historical rank and industry rank for RemeGen Co's Return-on-Tangible-Asset or its related term are showing as below:

FRA:REG' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -70.83   Med: -26.68   Max: 19.52
Current: 19.52

During the past 8 years, RemeGen Co's highest Return-on-Tangible-Asset was 19.52%. The lowest was -70.83%. And the median was -26.68%.

FRA:REG's Return-on-Tangible-Asset is ranked better than
95.26% of 1413 companies
in the Biotechnology industry
Industry Median: -35.77 vs FRA:REG: 19.52

RemeGen Co  (FRA:REG) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


RemeGen Co Return-on-Tangible-Asset Related Terms


RemeGen Co Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for RemeGen Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co Return-on-Tangible-Asset Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Asset
Get a 7-Day Free Trial 7.09 -19.62 -25.89 -27.63 11.01

RemeGen Co Quarterly Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.54 -29.50 0.00 -6.92 78.53

FRA:REG vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, RemeGen Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RemeGen Co Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Return-on-Tangible-Asset falls into.


FRA:REG
39GF Score
RemeGen Co Ltd FRA:REG
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RemeGen Co Return-on-Tangible-Asset Calculation

RemeGen Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=86.046/( (702.46+860.352)/ 2 )
=86.046/781.406
=11.01 %

RemeGen Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=611.28/( (696.39+860.352)/ 2 )
=611.28/778.371
=78.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2025) net income data.

What does a Return-on-Tangible-Asset of 78.53% mean?
RemeGen Co (FRA:REG) has a Return-on-Tangible-Asset of 78.53% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on RemeGen Co and its competitors. According to the industry distribution chart, RemeGen Co ranks #67 out of 1413 companies in the Biotechnology industry, placing it in the top 4.7%.
Is RemeGen Co's Return-on-Tangible-Asset too high?
RemeGen Co's current Return-on-Tangible-Asset is 78.53%. Based on the distribution chart, RemeGen Co ranks #67 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RemeGen Co has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #67 out of 1413 companies for Return-on-Tangible-Asset. This places RemeGen Co in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on RemeGen Co and its competitors. RemeGen Co's current Return-on-Tangible-Asset is 78.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €21.08, compared to a current price of €9.36 — trading 55.6% below its estimated fair value. The current Return-on-Tangible-Asset is 78.53%. RemeGen Co's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Return-on-Tangible-Asset is 78.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RemeGen Co (FRA:REG) Overvalued in 2026?

Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued. The current stock price of €9.36 is trading 55.6% below its estimated GF Value™ of €21.08. GuruFocus considers RemeGen Co to be Possible Value Trap.

Key valuation signals for FRA:REG:

  • Return-on-Tangible-Asset: 78.53%
  • GF Value™: €21.08 vs. price of €9.36 (55.6% below fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RemeGen Co Business Description

Address 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
39GF Score

Get the complete analysis for FRA:REG

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.36
Price
€21.08
GF Value